Article Versions Notes

Shabir H, Hashemi S, Al-Rufayie M, Adelowo T, Riaz U, Ullah U, Alam B, Anwar M, de Preux L. Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome. International Journal of Environmental Research and Public Health. 2021; 18(16):8743. https://doi.org/10.3390/ijerph18168743

Shabir, Habiba, Sana Hashemi, Moussa Al-Rufayie, Tayo Adelowo, Umar Riaz, Umayair Ullah, Benyamin Alam, Mehreen Anwar, and Laure de Preux. 2021. "Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome" International Journal of Environmental Research and Public Health 18, no. 16: 8743. https://doi.org/10.3390/ijerph18168743

Shabir, H., Hashemi, S., Al-Rufayie, M., Adelowo, T., Riaz, U., Ullah, U., Alam, B., Anwar, M., & de Preux, L. (2021). Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome. International Journal of Environmental Research and Public Health, 18(16), 8743. https://doi.org/10.3390/ijerph18168743